Olumiant

What Olumiant is used for

Rheumatoid arthritis Baricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate. Atopic Dermatitis Olumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. Alopecia areata Baricitinib is indicated for the treatment of severe alopecia areata in adult and adolescent patients 12 years of age and older. Juvenile idiopathic arthritis Baricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs: Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular), Enthesitis related arthritis, and Juvenile psoriatic arthritis. Baricitinib may be used as monotherapy or in combination with methotrexate.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Olumiant

Active substance

baricitinib

Disease area

Arthritis, Rheumatoid

Medicine group

Immunosuppressants

ATC code

L04AA37

Marketing authorisation holder

Eli Lilly Nederland B.V.

Authorised in the EU since

2017

Official information

• Olumiant: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In the USA

Same active substance: Olumiant

In India

• Baricitinib: 9 brands in India